A mechanistic study to determine the relevance of Benralizumab targets (eosinophil-numbers and IL5-receptor) in patients with skin disorders. - ROBERTIS (Relevance of Benralizumab targets in skin disorders)
Latest Information Update: 23 Jul 2019
At a glance
- Drugs Benralizumab (Primary)
- Indications Atopic dermatitis; Bullous pemphigoid; Dermatitis herpetiformis; Granuloma annulare; Mycosis fungoides; Prurigo; Urticaria
- Focus Pharmacodynamics
- Acronyms ROBERTIS
- 15 Jul 2019 Status changed from recruiting to completed.
- 13 Dec 2017 New trial record